143 related articles for article (PubMed ID: 21350921)
1. Effect of blood decrease on micafungin disposition in rats.
Konishi H; Fukushima K; Sudo M; Sumi M; Minouchi T; Iga I; Shibata N; Yamaji A
Eur J Drug Metab Pharmacokinet; 2011 Mar; 36(1):35-9. PubMed ID: 21350921
[TBL] [Abstract][Full Text] [Related]
2. Reduced elimination clearance of micafungin in rats with cholestatic hyperbilirubinemia.
Konishi H; Fukushima K; Sudo M; Sumi M; Minouchi T; Iga I; Shibata N; Takada K; Yamaji A
Fundam Clin Pharmacol; 2010 Aug; 24(4):457-62. PubMed ID: 19845766
[TBL] [Abstract][Full Text] [Related]
3. Impact of plasma exchange on pharmacokinetic disposition of micafungin.
Konishi H; Fukushima K; Saotome T; Hamamoto T; Eguchi Y; Sudo M; Sumi M; Minouchi T; Iga I; Yamaji A
Ther Apher Dial; 2010 Jun; 14(3):358-63. PubMed ID: 20609192
[TBL] [Abstract][Full Text] [Related]
4. Effect of liver and kidney function on migafungin disposition in patients with hematologic malignancies.
Nakagawa Y; Ichii Y; Saeki Y; Kodama M; Kishino S; Suzuki K
Eur J Drug Metab Pharmacokinet; 2008; 33(3):191-8. PubMed ID: 19007046
[TBL] [Abstract][Full Text] [Related]
5. Penetration of micafungin into the burn eschar in patients with severe burns.
Sasaki J; Yamanouchi S; Sato Y; Abe S; Shinozawa Y; Kishino S; Aikawa N; Hori S
Eur J Drug Metab Pharmacokinet; 2014 Jun; 39(2):93-7. PubMed ID: 23771854
[TBL] [Abstract][Full Text] [Related]
6. In vitro investigation of the hepatobiliary disposition mechanisms of the antifungal agent micafungin in humans and rats.
Yanni SB; Augustijns PF; Benjamin DK; Brouwer KL; Thakker DR; Annaert PP
Drug Metab Dispos; 2010 Oct; 38(10):1848-56. PubMed ID: 20606004
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of micafungin in patients undergoing allogeneic hematopoietic stem cell transplantation.
Oshima K; Kanda Y; Kako S; Ohno K; Kishino S; Kurokawa M
Transpl Infect Dis; 2013 Jun; 15(3):323-7. PubMed ID: 23578224
[TBL] [Abstract][Full Text] [Related]
8. Safety, tolerability, and feasibility of antifungal prophylaxis with micafungin at 2 mg/kg daily in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation.
Yoshikawa K; Nakazawa Y; Katsuyama Y; Hirabayashi K; Saito S; Shigemura T; Tanaka M; Yanagisawa R; Sakashita K; Koike K
Infection; 2014 Aug; 42(4):639-47. PubMed ID: 24567233
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic behavior of micafungin in rats with carbon tetrachloride-induced acute hepatic failure.
Konishi H; Sudo M; Sumi M; Morii H; Minouchi T; Aimoto T; Yamaji A
Biol Pharm Bull; 2005 Mar; 28(3):556-9. PubMed ID: 15744091
[TBL] [Abstract][Full Text] [Related]
10. Involvement of multidrug resistance-associated protein 2 (ABCC2/Mrp2) in biliary excretion of micafungin in rats.
Abe F; Ueyama J; Kimata A; Kato M; Hayashi T; Nadai M; Saito H; Takeyama N; Noguchi H; Hasegawa T
Life Sci; 2008 Aug; 83(7-8):229-35. PubMed ID: 18638490
[TBL] [Abstract][Full Text] [Related]
11. Role of plasma proteins in pharmacokinetics of micafungin, an antifungal antibiotic, in analbuminemic rats.
Abe F; Ueyama J; Kawasumi N; Nadai M; Hayashi T; Kato M; Ohnishi M; Saito H; Takeyama N; Hasegawa T
Antimicrob Agents Chemother; 2008 Sep; 52(9):3454-6. PubMed ID: 18591270
[TBL] [Abstract][Full Text] [Related]
12. Distribution of micafungin in the tissue fluids of patients with invasive fungal infections.
Yamada N; Kumada K; Kishino S; Mochizuki N; Ohno K; Ogura S
J Infect Chemother; 2011 Oct; 17(5):731-4. PubMed ID: 21537970
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic and safety profiles of repeated-dose prophylactic micafungin in children and adolescents undergoing hematopoietic stem cell transplantation.
Albano E; Azie N; Roy M; Townsend R; Arrieta A
J Pediatr Hematol Oncol; 2015 Jan; 37(1):e45-50. PubMed ID: 25072363
[TBL] [Abstract][Full Text] [Related]
14. Higher clearance of micafungin in neonates compared with adults: role of age-dependent micafungin serum binding.
Yanni SB; Smith PB; Benjamin DK; Augustijns PF; Thakker DR; Annaert PP
Biopharm Drug Dispos; 2011 May; 32(4):222-32. PubMed ID: 21449041
[TBL] [Abstract][Full Text] [Related]
15. Endotoxin does not alter the pharmacokinetics of micafungin, but it impairs biliary excretion of micafungin via multidrug resistance-associated protein 2 (ABCC2/Mrp2) in rats.
Noda T; Abe F; Ueyama J; Kato M; Katoh M; Nadai M; Saito H; Hasegawa T
J Infect Chemother; 2011 Apr; 17(2):207-13. PubMed ID: 20835743
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of prophylactic micafungin in very-low-birth-weight infants.
Kawada M; Fukuoka N; Kondo M; Okazaki K; Kusaka T; Kawada K; Itoh S
Pediatr Infect Dis J; 2009 Sep; 28(9):840-2. PubMed ID: 19636279
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of micafungin in neonates and young infants.
Hope WW; Smith PB; Arrieta A; Buell DN; Roy M; Kaibara A; Walsh TJ; Cohen-Wolkowiez M; Benjamin DK
Antimicrob Agents Chemother; 2010 Jun; 54(6):2633-7. PubMed ID: 20308367
[TBL] [Abstract][Full Text] [Related]
18. Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits.
Groll AH; Mickiene D; Petraitis V; Petraitiene R; Ibrahim KH; Piscitelli SC; Bekersky I; Walsh TJ
Antimicrob Agents Chemother; 2001 Dec; 45(12):3322-7. PubMed ID: 11709303
[TBL] [Abstract][Full Text] [Related]
19. Bronchopulmonary disposition of micafungin in healthy adult volunteers.
Nicasio AM; Tessier PR; Nicolau DP; Knauft RF; Russomanno J; Shore E; Kuti JL
Antimicrob Agents Chemother; 2009 Mar; 53(3):1218-20. PubMed ID: 19114675
[TBL] [Abstract][Full Text] [Related]
20. Ocular distribution of intravenously administered micafungin in rabbits.
Suzuki T; Uno T; Chen G; Ohashi Y
J Infect Chemother; 2008 Jun; 14(3):204-7. PubMed ID: 18574655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]